logo
welcome
CNBC

CNBC

Healthy Returns: Eli Lilly gains momentum against Novo Nordisk in the weight loss drug market

CNBC
Summary
Nutrition label

88% Informative

" Lilly is pulling ahead in the metabolic duopoly," BMO Capital Markets analyst Evan Seigerman said.

Eli Lilly's weight loss injection Zepbound and diabetes treatment Mounjaro smashed expectations for the second quarter .

Novo Nordisk trimmed its full-year profit outlook after sales of Wegovy came in well below Wall Street expectations.

Stryker says the acquisition is subject to customary closing conditions.

Terms of the deal were not disclosed.

"Our commitment to simplifying and enhancing the lives of healthcare professionals and patients remains unwavering," CEO Chakri Toleti says.

The technology Care.ai offers will "integrate seamlessly" with Strykers ' platforms and devices, company says.